270 related articles for article (PubMed ID: 20066428)
1. Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2.
Vihola A; Bachinski LL; Sirito M; Olufemi SE; Hajibashi S; Baggerly KA; Raheem O; Haapasalo H; Suominen T; Holmlund-Hampf J; Paetau A; Cardani R; Meola G; Kalimo H; Edström L; Krahe R; Udd B
Acta Neuropathol; 2010 Apr; 119(4):465-79. PubMed ID: 20066428
[TBL] [Abstract][Full Text] [Related]
2. Comparative transcriptional and biochemical studies in muscle of myotonic dystrophies (DM1 and DM2).
Salvatori S; Furlan S; Fanin M; Picard A; Pastorello E; Romeo V; Trevisan CP; Angelini C
Neurol Sci; 2009 Jun; 30(3):185-92. PubMed ID: 19326042
[TBL] [Abstract][Full Text] [Related]
3. Alternative splicing of human insulin receptor gene (INSR) in type I and type II skeletal muscle fibers of patients with myotonic dystrophy type 1 and type 2.
Santoro M; Masciullo M; Bonvissuto D; Bianchi ML; Michetti F; Silvestri G
Mol Cell Biochem; 2013 Aug; 380(1-2):259-65. PubMed ID: 23666741
[TBL] [Abstract][Full Text] [Related]
4. Gene expression analysis in myotonic dystrophy: indications for a common molecular pathogenic pathway in DM1 and DM2.
Botta A; Vallo L; Rinaldi F; Bonifazi E; Amati F; Biancolella M; Gambardella S; Mancinelli E; Angelini C; Meola G; Novelli G
Gene Expr; 2007; 13(6):339-51. PubMed ID: 17708420
[TBL] [Abstract][Full Text] [Related]
5. Altered expression and splicing of Ca(2+) metabolism genes in myotonic dystrophies DM1 and DM2.
Vihola A; Sirito M; Bachinski LL; Raheem O; Screen M; Suominen T; Krahe R; Udd B
Neuropathol Appl Neurobiol; 2013 Jun; 39(4):390-405. PubMed ID: 22758909
[TBL] [Abstract][Full Text] [Related]
6. Most expression and splicing changes in myotonic dystrophy type 1 and type 2 skeletal muscle are shared with other muscular dystrophies.
Bachinski LL; Baggerly KA; Neubauer VL; Nixon TJ; Raheem O; Sirito M; Unruh AK; Zhang J; Nagarajan L; Timchenko LT; Bassez G; Eymard B; Gamez J; Ashizawa T; Mendell JR; Udd B; Krahe R
Neuromuscul Disord; 2014 Mar; 24(3):227-40. PubMed ID: 24332166
[TBL] [Abstract][Full Text] [Related]
7. Analysis of MTMR1 expression and correlation with muscle pathological features in juvenile/adult onset myotonic dystrophy type 1 (DM1) and in myotonic dystrophy type 2 (DM2).
Santoro M; Modoni A; Masciullo M; Gidaro T; Broccolini A; Ricci E; Tonali PA; Silvestri G
Exp Mol Pathol; 2010 Oct; 89(2):158-68. PubMed ID: 20685272
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of muscle atrophy in myotonic dystrophies.
Timchenko L
Int J Biochem Cell Biol; 2013 Oct; 45(10):2280-7. PubMed ID: 23796888
[TBL] [Abstract][Full Text] [Related]
9. Flies deficient in Muscleblind protein model features of myotonic dystrophy with altered splice forms of Z-band associated transcripts.
Machuca-Tzili L; Thorpe H; Robinson TE; Sewry C; Brook JD
Hum Genet; 2006 Nov; 120(4):487-99. PubMed ID: 16927100
[TBL] [Abstract][Full Text] [Related]
10. Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy.
Fugier C; Klein AF; Hammer C; Vassilopoulos S; Ivarsson Y; Toussaint A; Tosch V; Vignaud A; Ferry A; Messaddeq N; Kokunai Y; Tsuburaya R; de la Grange P; Dembele D; Francois V; Precigout G; Boulade-Ladame C; Hummel MC; Lopez de Munain A; Sergeant N; Laquerrière A; Thibault C; Deryckere F; Auboeuf D; Garcia L; Zimmermann P; Udd B; Schoser B; Takahashi MP; Nishino I; Bassez G; Laporte J; Furling D; Charlet-Berguerand N
Nat Med; 2011 Jun; 17(6):720-5. PubMed ID: 21623381
[TBL] [Abstract][Full Text] [Related]
11. Distinct pathological signatures in human cellular models of myotonic dystrophy subtypes.
Kim EY; Barefield DY; Vo AH; Gacita AM; Schuster EJ; Wyatt EJ; Davis JL; Dong B; Sun C; Page P; Dellefave-Castillo L; Demonbreun A; Zhang HF; McNally EM
JCI Insight; 2019 Mar; 4(6):. PubMed ID: 30730308
[TBL] [Abstract][Full Text] [Related]
12. Alternative splicing alterations of Ca2+ handling genes are associated with Ca2+ signal dysregulation in myotonic dystrophy type 1 (DM1) and type 2 (DM2) myotubes.
Santoro M; Piacentini R; Masciullo M; Bianchi ML; Modoni A; Podda MV; Ricci E; Silvestri G; Grassi C
Neuropathol Appl Neurobiol; 2014 Jun; 40(4):464-76. PubMed ID: 23888875
[TBL] [Abstract][Full Text] [Related]
13. Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds.
Arandel L; Polay Espinoza M; Matloka M; Bazinet A; De Dea Diniz D; Naouar N; Rau F; Jollet A; Edom-Vovard F; Mamchaoui K; Tarnopolsky M; Puymirat J; Battail C; Boland A; Deleuze JF; Mouly V; Klein AF; Furling D
Dis Model Mech; 2017 Apr; 10(4):487-497. PubMed ID: 28188264
[TBL] [Abstract][Full Text] [Related]
14. Aberrant splicing and expression of the non muscle myosin heavy-chain gene MYH14 in DM1 muscle tissues.
Rinaldi F; Terracciano C; Pisani V; Massa R; Loro E; Vergani L; Di Girolamo S; Angelini C; Gourdon G; Novelli G; Botta A
Neurobiol Dis; 2012 Jan; 45(1):264-71. PubMed ID: 21872659
[TBL] [Abstract][Full Text] [Related]
15. Muscle pathology in myotonic dystrophy: light and electron microscopic investigation in eighteen patients.
Nadaj-Pakleza A; Lusakowska A; Sułek-Piątkowska A; Krysa W; Rajkiewicz M; Kwieciński H; Kamińska A
Folia Morphol (Warsz); 2011 May; 70(2):121-9. PubMed ID: 21630234
[TBL] [Abstract][Full Text] [Related]
16. Genome wide identification of aberrant alternative splicing events in myotonic dystrophy type 2.
Perfetti A; Greco S; Fasanaro P; Bugiardini E; Cardani R; Garcia-Manteiga JM; Riba M; Cittaro D; Stupka E; Meola G; Martelli F
PLoS One; 2014; 9(4):e93983. PubMed ID: 24722564
[TBL] [Abstract][Full Text] [Related]
17.
Bosè F; Renna LV; Fossati B; Arpa G; Labate V; Milani V; Botta A; Micaglio E; Meola G; Cardani R
Front Neurol; 2019; 10():992. PubMed ID: 31611837
[TBL] [Abstract][Full Text] [Related]
18. Altered mRNA splicing of the skeletal muscle ryanodine receptor and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase in myotonic dystrophy type 1.
Kimura T; Nakamori M; Lueck JD; Pouliquin P; Aoike F; Fujimura H; Dirksen RT; Takahashi MP; Dulhunty AF; Sakoda S
Hum Mol Genet; 2005 Aug; 14(15):2189-200. PubMed ID: 15972723
[TBL] [Abstract][Full Text] [Related]
19. Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2.
Timchenko L
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142405
[TBL] [Abstract][Full Text] [Related]
20. Myotonic Dystrophy: an RNA Toxic Gain of Function Tauopathy?
Fernandez-Gomez F; Tran H; Dhaenens CM; Caillet-Boudin ML; Schraen-Maschke S; Blum D; Sablonnière B; Buée-Scherrer V; Buee L; Sergeant N
Adv Exp Med Biol; 2019; 1184():207-216. PubMed ID: 32096040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
